【热门产品推荐】派安普利单抗，Penpulimab， AntibodySystem Laboratories
派安普利单抗，Penpulimab，CAS: 2350298-92-7，AntibodySystem Laboratories
货号：DHH02225
产品链接：http://www.atagenix.com/product_detail-74831.html
别名：AK-105, CAS: 2350298-92-7
简介：
派安普利单抗 Penpulimab 是一种 IgG1 抗 PD-1 单克隆抗体，具有抗肿瘤活性。
货号：DHH02225
产品品牌：Antibodysystem
通用名：Penpulimab
纯度：>95% by SDS-PAGE.
浓度：1mg/ml
Formulationicon：0.01M PBS, pH 7.4.
内毒素：Please contact with the lab for this information.
别名：AK-105
靶点;物种：Human CD279/PDCD1/PD1
种类：Humanized
受体鉴定：IgG1-Kappa
CAS: 2350298-92-7
存储条件：
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Store at +4°C short term (1-2 weeks).
Store at -20 °C 12 months.
Store at -80°C long term.
参考文献：
Penpulimab: First Approval. PMID: 34813051
Antibodies to watch in 2022. PMID: 35030985
Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers. PMID: 35165764
Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events. PMID: 35833116
Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203). PMID: 34327136
Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201). PMID: 35875118
Corrigendum: Successful treatment of a patient with multiple-line relapsed extensive-stage small-cell lung cancer receiving penpulimab combined with anlotinib: A case report. PMID: 36033531
Autoimmune hemolytic anemia in patients with relapsed Hodgkin's lymphoma after treatment with penpulimab, a monoclonal antibody against programmed death receptor-1. PMID: 35503192
Successful Treatment of a Patient With Multiple-Line Relapsed Extensive-Stage Small-Cell Lung Cancer Receiving Penpulimab Combined With Anlotinib: A Case Report. PMID: 35321433
